Fast Biopharma
Pre-clinicalCell death is a devastating component of a spectrum of diseases and results in severe morbidity. FasT Biopharma’s candidate therapeutics block a major pathway involved in the unwanted death of cells, providing potential breakthrough therapies.
Founded
2020
Focus
AntibodiesBiologics
About
Cell death is a devastating component of a spectrum of diseases and results in severe morbidity. FasT Biopharma’s candidate therapeutics block a major pathway involved in the unwanted death of cells, providing potential breakthrough therapies.
Funding History
2Total raised: $18.5M
Series A$15MUndisclosedNov 15, 2022
Seed$3.5MUndisclosedJun 15, 2021
Company Info
TypePrivate
Founded2020
LocationLondon, United Kingdom
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile